Meeting Challenges in Asymmetric Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Meeting Challenges in Asymmetric Synthesis
Industry and academia advance novel approaches for achieving enanioselectivity.


Pharmaceutical Technology
Volume 36, Issue 9, pp. 48-50

Other catalytic approaches

BINOL and its derivatives are widely used classes of ligands in asymmetric synthesis, such as in Diels–Alder reactions, carbonyl addition, and reductions (7). Researchers at the University of Texas, Austin, recently developed a bifunctional catalyst derived from BINOL for producing highly enantioselective bromolactonizations of unsaturated carboxylic acids (8, 9). Specifically, the catalyst promoted highly enantioselective bromolactonizations of 4- and 5-aryl-4-pentenoic acids, but it also catalyzed the highly enantioselective bromolactonizations of 5-alkyl-4(Z)-pentenoic acids. The researchers assert that these reactions represent the first catalytic bromolactonizations of alkyl-substituted olefinic acids that proceeded by means of 5-exo mode cyclizations to give lactones in which new carbon–bromine bonds are formed at a stereogenic center with high enantioselectivity. The researchers also reported on what they say is the first catalytic desymmetrization of a prochiral dienoic acid by enantioselective bromolactonization (8, 9).

Patricia Van Arnum is executive editor of Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
twitter@PharmTechVArnum.

References

1 B. Halford, Chem. & Eng. News 90 (34), 9 (2012).

2. G. Coulthard, W. Erb, and K. Aggarwal, "Stereocontrolled Organocatalytic Synthesis of Prostagladin PGFin Seven Steps," Nature, online DOI10.1038/nature11411, Aug. 15, 2012.

3. M.J. Abrahamson, Angew. Chem. Int. Ed. Engl. 51 (16), 3969–3972 (2012).

4. T. Li et al., J. Am. Chem. Soc. 134 (14), 6467–6472 (2012).

5. P. Van Arnum, Pharm. Technol. 36 (5), 56–60 (2012).

6. B.M. Stoltz et al., Nature Chem. 4 (2) 130–133 (2012).

7. W. Sommer and D. Weibel, Aldrich ChemFiles 8.2 (56), 2008.

8. D.H. Paull, J. Am. Chem. Soc., 134 (27), pp 11128–11131 (2012).

9. C. Drahl, Chem. & Eng. News 90 (28), 29 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here